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Abstract 
 
The effect of milled and micronized lactose fines on the fluidization and in vitro aerosolization 
properties of dry powder inhaler (DPI) formulations was investigated, and the suitability of 
static and dynamic methods for characterising general powder flow properties of these 
blends was assessed. Lactose carrier pre-blends were prepared by adding different lactose 
fines (Lactohale 300, 230 and 210) with coarse carrier lactose (Lactohale100) at 2.5, 5, 10 
and 20 wt-% concentrations. Powder flow properties of lactose pre-blends were 
characterized using the Freeman Technology FT4 and Schulze RST-XS ring shear tester. A 
strong correlation was found between the basic flow energy (BFENorm) measured using the 
Freeman FT4 rheometer and the flowability number (ffc) measured on Schulze RST-XS. 
These data indicate that both static and dynamic methods are suitable for characterising 
general powder flow properties of lactose carriers. Increasing concentration of fines 
corresponded with an increase in the normalized fluidization energy (FENorm). The inclusion 
of fine particles of lactose resulted in a significant (p<0.05) increase in fine particle delivery 
of budesonide, and correlated with FENorm. This trend was strongest for lactose containing up 
to 10 wt-% LH300. A similar trend was found for the milled lactose grades LH230 and 
LH210. However, the increase in FENorm upon addition of milled fines only corresponded to a 
very slight improvement in the performance. These data suggest that whilst the fluidization 
energy correlated with fine particle delivery, this relationship is specific to lactose grades of 
similar particle size.  
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Introduction 
 
Dry powder inhalers (DPI) are one of the most popular systems for delivering therapeutic 
agents for the treatment asthma and chronic obstructive pulmonary disease (COPD) via the 
lung (1). In carrier-based DPIs, the active pharmaceutical ingredient (API) is delivered to the 
lungs from a static powder bed that is fluidized and entrained by the airflow generated by the 
patient’s inspiratory effort (2). However, to enable the API to deposit in the lungs, the API 
must be micronized to achieve a particle size of less than 5 µm (3). In terms of their 
fluidization properties, micronized powders are classified as Geldart group C powders, which 
are cohesive and difficult to fluidize (4). This is mainly due to the ubiquitous van der Waals 
interactions, which dominate the gravitational forces acting on particles finer than 10 µm (5). 
The highly cohesive nature of micronized materials prevents accurate metering of the low 
doses required for inhaled drug products, and renders the material difficult to handle during 
the manufacturing process. To overcome the issues of handling and dosing, and to optimize 
the fluidization properties of DPI formulations, a micronized API is typically blended with a 
Geldart group A powder that can be easily aerated and fluidized (4). For carrier based DPI 
formulations, the Geldart group A granular material is a coarse sized fraction of lactose 
monohydrate.  
 
It is also well known that the extrinsic addition of lactose fines (a Geldart group C powder) to 
the coarse lactose carrier (Geldart group A powder) significantly enhances the aerosolization 
performance and delivery of the API (6,7). The traditional theories proposed for this 
mechanism of action are the active site theory (8,9) and fine particle multiplet  theory (6,7). 
The active site theory supports the hypothesis of the presence of high energy “hot-spots” on 
the surface of the coarse lactose. These “hot-spots” are preferentially occupied by the fine 
lactose particles allowing the API particles adhere to low energy sites from where they are 
readily dispersed upon inspiration (9-11). In contrast, the fine particle multiplet theory 
suggests that the improvement in DPI performance is due to the formation of mixed 
API/fines agglomerates that are better elutriated from the carrier particle surface than free 
API particles due to greater aerodynamic drag forces acting on the agglomerates (2,6,7). 
More recently, Shur et al., reported a third possible mechanism, which suggested that the 
addition of lactose fines increases the cohesive strength of the formulation that in turn leads 
to greater deagglomeration efficiencies and an increase in fine particle delivery (12). They 
suggested that the increased cohesive strength of the powder bed on the addition of fine 
lactose particles shifted the minimum fluidization velocity of the powder bed as result of 
increased inter-particulate forces in the bulk powder bed. Upon reaching the minimum 
fluidization velocity, the cohesive powder bed fractures and the powder is fluidized as 
agglomerates, which undergo increased number of high-energy particle-particle and particle-
device collisions. The increased energy from these collisions enhances API re-suspension 
(12). Whilst studies by Versteeg et al., and Tuley et al., have shown similar observations 
(13,14), Shur et al., related the different fluidization mechanisms for powder beds with high 
and low fines content to powder flow measurements performed using powder rheology (12). 
These findings suggest the specific relevance of the Geldart classification in defining the 
mechanism by which the addition of relatively small concentrations of lactose fines (Geldart 
group C powders) can directly affect the fluidization properties of an aeratable coarse 
lactose (Geldart group A powder). 
 
Therefore, as the flowability and fluidization behaviour may be particularly important in DPIs, 
the quantification of powder cohesion is considered to be advantageous. Powder rheology is 
a key approach to assess these properties and has the potential to provide valuable insight 
into the deagglomeration behaviour of DPIs. There are various commercially available 
instruments for measuring powder flow and fluidization properties, and powder rheology 
measurements can be divided into two different categories on the basis of the compaction 
state during the measurements (15); if the powder is compacted, the measurements are 
considered as static, and if the particles are able to move freely during the measurements 
the method is dynamic. For example, a Schulze ring shear tester falls into the static 
category, whereas the Freeman FT4 powder rheometer can be operated in both static and 
dynamic modes.  
 
The Schulze ring shear tester characterizes the powder flow properties in terms of flowability 
number ffc based on the incipient flow of the powder under pre-defined consolidation and 
shear stresses applied on the powder using theoretically well understood Mohr stress 
circles; for a comprehensive explanation of Mohr circles the reader is referred to (16). 
However, a brief description of the process of defining the ffc using the Mohr circles is 
provided in the following. To define the Mohr circles for a powder, a yield locus has to be 
constructed. This is done by shearing a powder sample until failure under several pre-
defined consolidation stresses (σ) and by plotting the consolidation stresses against the 
shear stresses (τ) at which the failure occurred. Based on the yield locus, two different Mohr 
stress circles for a powder under a certain stress can be constructed (16). One of the circles 
is constructed by using the end point of the yield locus, i.e. the pre-shear point (τPre, σPre), as 
intersect for the tangent between the yield locus and the larger Mohr circle. The larger Mohr 
circle defines the vertical consolidation stress (σ1) of the powder at the pre-sheared state, 
i.e. at steady flow. The smaller Mohr stress circle intersects the origin of the graph and is 
tangential to the yield locus. This stress circle represents the stresses in the powder if stored 
in a container without walls and is defined as the unconfined yield strength (σc). The flow 
function of a powder (ffc) is defined as the ratio between the consolidation stress σ1 and the 
unconfined yield strength σc as per Equation 1, and the larger the value of ffc for a powder, 
the better the flow properties it exhibits (16). 
 
    
  
  
     EQUATION 1 
 
In contrast, the FT4 Universal Powder Rheometer methodologies are generally based on an 
empirical approach. In the dynamic mode, the flow properties are measured by the energy 
(torque) required to rotate a helical blade at a set speed while simultaneously traversing the 
blade in or out of a powder bed (17). This energy is called the flow energy and is the product 
of all the forces acting on the rheometer blade during displacement of a powder sample (17). 
Changes in the flow energy of a powder can also be investigated upon aeration using a 
controlled, dry air supply fed through a porous stainless steel disc at the base of the testing 
vessel containing the powder. The air throughput is adjustable to allow various levels of air 
velocity to be established whilst the test is in progress. As the powder reaches its minimum 
fluidization velocity the flow energy decreases to a minimum and plateaus. This residual flow 
energy is the resistance that must be overcome to fluidize a material, and is described as the 
fluidization energy (18, 19, 20). 
 
Previous studies have indicated a correlation between the flow and fluidization properties of 
the carrier and the final DPI formulation performance (12,20-22). However, these studies 
were based on relatively small datasets and the carriers used have mainly been different 
coarse fractions of lactose. It has also been shown that the particle size distribution of the 
added fine lactose is an important factor in determining whether the DPI formulation 
performance increases as more lactose fines are added, with finer sub-cuts of the lactose 
known to be more effective in improving DPI performance (11, 23-25). Following on from the 
hypothesis of Shur et al. that increased cohesion of the carrier results to an increased DPI 
formulation performance (12), the study reported here aimed to investigate the influence of 
the addition of extrinsic lactose fines with different process histories (micronized vs. milled), 
and thus size distributions, to the bulk flow and fluidization properties of a wide range of 
different carriers, and aimed to investigate whether the increased cohesion would universally 
account for the improved DPI performance for a wide selection of lactose carriers. 
Furthermore, there appears to be no scientific literature comparing the results obtained by 
the different powder rheology systems available on the market, and therefore this study was 
also to investigate the correlation between the results obtained with the two different 
instruments specifically for a range of lactose pre-blends. 
 
Materials and methods 
 
Materials 
 
The different inhalation grades of lactose used in the study were Lactohale (LH) products 
(DFE Pharma, Goch, Germany) and were: a sieved grade coarse carrier LH100, micronized 
lactose fines LH300 and two different grades of milled lactose fines, LH230 and LH210. 
Micronized budesonide (Sterling S.r.l, Perugia, Italy) was used as received. The cohesive-
adhesive balance (CAB) value for the sourced micronized budesonide was determined as 
0.62 following a method described elsewhere (26), implying that the drug preferentially 
adhered to the lactose, with the interaction being 38% greater than the drug-drug interaction. 
Methanol and acetonitrile were of HPLC grade (Fisher Scientific, Loughborough, UK) and 
water was reverse osmosis purified. (Millipore, France). 
 
Methods 
 
Preparation of lactose pre-blends 
 
A series of lactose pre-blends were prepared (LH300 in LH100, LH230 in LH100 and LH210 
in LH100) at fines concentrations of 2.5, 5, 10 and 20 wt-% in quantities of 100 g by 
sandwiching each of the fines between LH100 in three layers in an earthed 500 cm3 
stainless steel vessel and blended using a Turbula T2F mixer (Glen Creston Ltd., Middlesex, 
UK) at 46 rpm for 60 minutes. The pre-blends were stored at 20 ± 2°C and 44% relative 
humidity (RH) for at least 24 hours before any further work or characterization was 
performed.  
 
Particle sizing of the raw materials and the pre-blends 
 
The particle size distributions of the lactose raw materials and the pre-blends were 
measured dispersed dry at a pressure of 2 bar using a Sympatec Helos laser diffraction 
system with an R4 lens in conjunction with a Rodos T4 disperser and a Vibri feeder, 
controlled by WINDOX software (all from Sympatec Gmbh, Germany). The feed rate was 
adjusted such that an optical concentration between 0.5 and 5% was obtained. Five repeat 
measurements were taken for each of the samples and the high resolution Fraunhofer model 
(HRLD) was applied for calculating the particle size distribution from the scattering data.  
 
Scanning electron microscopy 
 
The scanning electron microscopy (SEM) for the raw materials was performed on a JEOL 
JSM-6480LV SEM (JEOL, Tokyo, Japan). The samples were mounted on stainless steel 
sample holders using sticky carbon tabs and coated with an Edwards sputter coater S150B 
(BOC Edwards, UK) for 5.5 minutes prior to the analysis. An acceleration voltage of 10 kV 
was applied for imaging.  
 
Powder flow properties on the Schulze RST-XS 
 
The following procedure was followed for characterizing the samples on the RST-XS annular 
ring shear tester controlled by RST-Control 95 software (both from Dietmar Schulze, 
Germany). For each test, a 30 ml annular shear cell was filled with the powder under 
investigation without applying force to the upper surface of the powder bed. The powder was 
pre-sheared with a normal stress of 1000 Pa (τpre) until steady-state flow was achieved. A 
yield locus was then constructed by measuring the shear stress required to cause the 
powder to fail under three normal stresses lower than τpre (250 Pa, 500 Pa and 750 Pa). 
Each powder was tested three times and the mean flowability ratio (ffc) at 1000 Pa pre-shear 
stress was calculated following Equation 1. ffc is a  dimensionless parameter, which 
increases as powder flowability improves (27). Hence, the more cohesive the powder, the 
lower the value of ffc. 
 
Powder flow and fluidization properties on the FT4 
 
The flow and fluidization behaviour of the lactose pre-blends were also characterized using 
the FT4 Powder Rheometer (Freeman Technology, Tewkesbury, UK). The FT4 is a 
universal powder tester with a number of different measurement programs which can be run 
depending on the powder properties that are of interest. All the standard measurement 
programs, however, require a conditioning cycle or cycles of the powder prior to any 
measurement. Conditioning provides a gentle displacement of the powder removing the 
packing history of the powder and any operator differences, and thus generates a 
homogenized and uniform packing of the powder at low consolidation. During 
measurements, the torque and the force required to keep the impeller blade moving through 
the powder bed at a pre-programmed speed are measured as a function of the blade height 
within the powder bed. From these raw data, the flow energy of the powder can be 
calculated. In practice, a 25 mm bore diameter, 20 ml split vessel is filled with the powder 
under investigation before a conditioning cycle is run using a 23.5 mm blade that is moved 
downwards in a clockwise helical path with an angle of 5 degrees at 60 mm/s. The split 
vessel is then opened to achieve a constant powder mass in the vessel before a specific 
measurement program is run. During a measurement the blade is moved through the 
powder in an anti-clockwise motion at a tip speed of 100 mm/s and a helical angle of 5 
degrees unless otherwise stated. The normalized basic flow energy (BFENorm) is the energy 
required to move the blade through a gram of powder. Flow rate index (FRI) is a 
dimensionless parameter that is the ratio between the flow energy of the powder at anti-
clockwise blade motions of 10 mm/s and 100 mm/s and normalized fluidization energy 
(FENorm) is the energy required to move the blade through a gram of powder in an anti-
clockwise motion at 100 mm/s tip speed at the minimum fluidization velocity of each of the 
powders.  
 
Preparation of carrier-based DPI formulations with budesonide 
 
The lactose pre-blends were formulated with budesonide at 0.8 wt-% concentration to 
produce an array of model DPI formulations for in vitro testing. The formulations were 
prepared in quantities of 40 g by using the same stainless steel vessel as for preparing the 
lactose pre-blends. The lactose pre-blends were sieved with an 850 µm aperture sieve to 
break any large agglomerates present in the pre-blends prior to formulation processing. The 
drug (0.32 g) was weighed and sandwiched between half of the mass of the lactose pre-
blend and blended in a Turbula at 46 rpm for 10 minutes. The remaining mass of lactose 
was then added and blending was continued for a further 45 minutes. The formulations were 
sieved with a 250 µm aperture sieve to break any large agglomerates that may have formed 
and the formulations stored at 20 ± 2°C and 44% RH for at least 24 hours before any testing 
or capsule filling. The drug content uniformity of the blends was measured by taking ten 
random samples of 12.5 mg and determining the amount of drug in the samples by high 
performance liquid chromatography (HPLC).  
 
Drug content assay by HPLC 
 
The drug content was determined using a validated high performance liquid chromatography 
(HPLC) method (26), which utilized a 250 mm ODS C18 5 µm Hypersil column with an 
internal diameter of 4.6 mm (Thermo, Fisher Scientific, Loughborough, UK) with the oven 
(Jasco CO-965, Jasco, Japan) temperature set to 40°C. The mobile phase, which consisted 
of 45% methanol, 35% acetonitrile and 20% water, was pumped through the system at a 
flow rate of 1.5 ml/min (Jasco PU-980, Jasco, Japan). 200 µl aliquots of the drug dissolved 
in the mobile phase were injected with the autosampler (Jasco AS-950, Jasco, Japan). 
Ultraviolet (UV) detection (Jasco UV-975, Jasco, Japan) at a wavelength of 244 nm was 
used for quantifying the amount of budesonide, which had a retention time of 3.75 minutes.  
 
In vitro testing of the formulations 
 
The in vitro performance of the formulations was tested using a Next Generation Impactor 
(NGI) equipped with a pre-separator (Copley Scientific, Nottingham, UK). Prior to testing, the 
pre-separator was filled with 15 ml of mobile phase. The NGI cups were coated with 1 %v/v 
silicone oil in hexane to eliminate particle bounce. Hand-filled size 3 
hydroxypropylmethylcellulose (HPMC) capsules, containing 12.5 mg of the formulation each, 
were aerosolized into the NGI using a Rotahaler (GlaxoSmithKline, UK) and Handihaler 
(Boehringer Ingelheim, Germany) DPI devices. The flow rate was adjusted using the TPK 
critical flow control unit (Copley Scientific, Nottingham, UK) to 90 L/min for the Rotahaler and 
to 52 L/min for the Handihaler, which is the upper achievable flow rate through the 
Handihaler device (28). The duration of aerosolization was adjusted for a time representative 
of an inhaled volume of 4 L. Following aerosolization of two capsules, the NGI apparatus 
was dismantled and each part of the NGI washed down into known volumes with the HPLC 
mobile phase. The mass of drug deposited on each stage of the NGI, mouthpiece and inlet 
throat, pre-separator and the device was determined by HPLC. This protocol was repeated 
in triplicate for each formulation. To compare the performance of the formulations on 
Rotahaler and Handihaler, results were normalized by obtaining the mean mass 
aerodynamic diameters (MMAD) and the fine particle fraction of particles less than 5 µm 
calculated by extrapolation (28). The fine particle fraction was normalized to the emitted 
dose (FPFED). 
 
Analysis of statistical significance 
 
Statistical analysis of the results was performed using Minitab v15 software (Minitab Inc., 
Pennsylvania, USA). Comparisons were performed using one-way analysis of variance 
(ANOVA) with Fisher comparison confidence level set to 95% or 99% depending on the 
outputs evaluated.  
 
  
Results and discussion 
 
Particle size distributions and morphology of the raw materials 
Representative SEM photomicrographs of the coarse lactose carrier and lactose fines are 
shown in Fig. 1. The coarse lactose carrier LH100 (Fig. 1A) exhibited a typical tomahawk 
morphology of lactose monohydrate, with intrinsic fine lactose particles adhered to the 
surface. Particles of micronized lactose (LH300) were below 20 µm and had irregular 
morphology (Fig. 1B). The micrographs of milled fines of LH230 and LH210 are shown in 
Fig. 1C and Fig. 1D, respectively. Both grades of milled fines were composed of particles 
with wider particle size distributions. In both these milled materials, only a small proportion of 
the particles were less than 5 µm. The coarser particles made up the bulk of the milled 
lactose materials and it is worth noting that the very fine lactose particles were adhering to 
the surfaces of these larger particles. The size and morphology of these particles was 
consistent with the proprietary milling process by which they are manufactured. However, 
the milling process is not as intense as air-jet micronization that is used for production of the 
micronized fines and therefore there was less generation of fine lactose particles.  
The particle size distributions of the coarse (LH100) and the lactose fines, as measured by 
laser diffraction, are summarized in Table I. Coarse carrier lactose (LH100) had a d50 of 
101.6 µm, whilst micronized lactose (LH300) had a median particle size of 2.41 µm, with 
90% of the particles finer than 7.76 µm. Of the two milled fines used in the study, LH230 
particles exhibited the smaller particle size distribution, with a d50 of 8.05 µm compared to a 
d50 of 14.30 µm for LH210 grade. These particle sizes are in agreement with the 
specifications of these commercial products (d50 of LH300 < 5 µm, LH230 < 10 µm and 
LH210 < 20 µm). 
 
Particle size distributions of the lactose pre-blends 
 
The proportion of fine lactose particles in the carrier has been reported in many studies to 
affect the performance of DPI formulations (24,25,29). The particle size distributions and the 
proportion of particles finer than 4.5 µm and 30 µm of the different lactose pre-blends are 
summarized in Table II. The proportion of intrinsic lactose fines less than 4.5 µm associated 
with the batch of LH100 was 1.3%. Upon the initial addition of 2.5 wt-% of micronized 
(LH300) fines to the coarse carrier (LH100), the proportion of particles <4.5 µm increased to 
4.9%. Upon increasing the concentration of the micronized component (LH300) to 5, 10 and 
20 wt-%, the cumulative percentage of fines below 4.5 µm present in the carrier blends 
increased to approximately 9, 17 and 23%, respectively (Table II). Table II also shows that 
the addition of the LH230 fines at 2.5, 5 and 10 wt-% concentrations resulted in 2.8, 4.3 and 
7.2% proportion of particles below 4.5 µm, respectively. A concentration of 20 wt-% was 
required to initiate a more pronounced contribution towards the fine end of the particle size 
distribution, whereby the percentage of particles <4.5 µm increased to approximately 12.5%. 
The addition of the LH210 fines had a very small contribution on the fines content of the 
carrier. Even upon the addition of 20 wt-%, the proportion of fine lactose particles <4.5 µm 
was only 6%. These data are as expected based on the fine particle content of the different 
grades of fine lactose used for preparing the pre-blends. 
 
Powder flow and fluidization properties of the lactose carriers 
The powder flow properties of the lactose pre-blends in terms of flowability number ffc 
measured on the Schulze RST-XS are summarized in Table III. Powder cohesion can be 
classified according to the ffc number; powders with ffc values between 2 and 4 are classified 
as cohesive and powders with values from 4 to 10 as free flowing (16). The data in Table III 
indicate that, of the lactose pre-blends used in this study, the 5, 10 and 20 wt-% blends of 
both the micronized LH300 and milled LH230 fines were classified as cohesive according to 
their ffc numbers. In the case of LH210, an addition of at least 10 wt-% of the fines was 
required for the pre-blends to be classified as cohesive.  
The corresponding values of the normalized basic flow energy (BFENorm) of the lactose 
carriers using the FT4 are summarized in Table III. When comparing the values of BFENorm 
to the ffc values, it was found that a BFENorm less than 20 mJ/g is associated with the 
formation of cohesive lactose pre-blends. The values of flow rate index (FRI) for the lactose 
pre-blends used in the current study are also summarized in Table III. The addition of 20 wt-
% LH300 to LH100 increased the FRI to 2.41 compared to 1.02 for the LH100. The 
corresponding values for 20 wt-% LH230 and LH210 blends are 1.81 and 1.41, respectively. 
These data suggest that LH300 had the largest, whilst the LH210 fines had the smallest 
impact on the powder flow properties across the concentration range investigated. 
As fluidization is a key step in delivering medication from a DPI formulation, characterization 
of the flow properties of the pre-blends under different states of aeration was also 
undertaken. The normalized fluidization energy (FENorm) measurements of the carrier blends 
are summarized in Table III. The increasing addition of LH230 had the largest impact on the 
FENorm, with 20 wt-% addition resulting in a value of 1.93 mJ/g compared to 0.70 mJ/g for 
LH100. The addition of LH300 increased the FENorm gradually with increasing levels of fines, 
with a value of 1.75 mJ/g for the 20 wt-% pre-blend. The addition of LH210 had very little 
impact on FENorm at concentrations ≤ 10 wt-%. The addition of 20 wt-% was required for a 
more pronounced effect on the FENorm to a value of 1.60 mJ/g.  
In summary, all the different parameters describing powder flow and fluidization 
characteristics suggest that the addition of the lactose fines into coarse lactose fractions 
does increase the cohesive properties of the carrier pre-blends.  
Validation of BFENorm and FRI as measures of powder cohesion 
The flow function (ffc), BFENorm and FRI are all measures of powder cohesion, which is an 
important powder property for formulation processing. Measuring the powder flow properties 
using a shear cell tester (ffc) is an established and widely accepted technique as the 
principles can be theoretically explained by Mohr circles (16,27). The dynamic approach 
used for example by the Freeman Technology FT4 powder rheometer (BFENorm and FRI) on 
the other hand is empirical and relies on characterizing differences amongst a group of 
powders based on their resistance to flow under a bulldozing action of an impeller blade, and 
relating the measurement results to the observed powder bulk behaviour during processing 
(17). Some theoretical work has been carried out to gain greater understanding of the 
powder properties affecting the results obtained on the dynamic FT4 system (30), but to 
date, the authors are not aware of experimental studies where the results obtained with the 
two different techniques have been compared. Therefore, to compare the results obtained by 
the two different techniques, and to validate the rheometry results obtained on the FT4 in 
this study, measurements of the lactose pre-blends were performed alongside Schulze RST-
XS ring shear testing. 
The ffc values measured on the RST-XS system and BFENorm measured on the FT4 for the 
different lactose pre-blends are plotted against each other in Fig. 2. There is a correlation 
between ffc and BFENorm over a range of lactose pre-blends containing either micronized or 
milled fines. The correlation suggests that for the lactose samples studied, the BFENorm 
measurements on the FT4 are comparable to the ffc, and can be applied as a descriptor for 
the general powder flow properties for lactose blends containing either micronized or milled 
fines. However, while a correlation has been observed here for the series of lactose pre-
blends, it has been suggested that such a correlation may not exist if a series of chemically 
different materials are characterized with static and dynamic measurement methods (15,17). 
The FRI of the lactose carriers investigated in the current study are plotted against the 
flowability number ffc in Fig. 3. The plot demonstrates a correlation between the FRI and ffc, 
and indicates that for free-flowing lactose carriers (ffc > 4), the FRI was insensitive in 
distinguishing between powders with different cohesive properties. However, once ffc was 
less than 3, the flow rate index became sensitive to the changes in the powder flow 
properties. These data suggest therefore that the FRI is relatively insensitive to Geldart type 
A powders, while being sensitive to the addition of Geldart type C powders at concentrations 
sufficient to affect its cohesive properties. This finding can be explained by the fact that FRI 
is known to be sensitive to the packing structure, and more precisely the air content, of the 
powder (17). Particles in free flowing powders pack closely and consequentially have low air 
content, and therefore altering the flow rate does not alter the contact between adjacent 
particles. In cohesive powders, on the other hand, air pockets remain within the powder 
packing structure. At slower flow rates the air has more time to escape, and thus the force 
transmission zone ahead of the blade extends upon slowing the flow rate, As a consequence 
the flow energy and FRI are increased (17).  
 
The results presented in this section indicate that both the ffc and BFENorm can be used for 
characterizing the general flow properties of lactose carriers used in DPI formulations. The 
results also suggest that in case of cohesive powders, FRI may provide additional insight 
into the general flow behaviour of the carrier pre-blends. 
 
Mechanism by which the fine particle lactose regulates powder flow and fluidization 
properties 
 
To investigate the link between the fine particle content of the carrier blends and their flow 
and fluidization properties, and to understand how the micronized and milled lactose fines 
increase the cohesion of the bulk powder, the ffc values of the lactose carriers are plotted 
against the proportion of particles finer than 4.5 µm present in the pre-blends in Figure 4A. 
The figure demonstrates that the ffc values for micronized fines (LH300) follow a very 
different trend to both the milled fines grades (LH230 and LH210). However, if the ffc is 
plotted against the proportion of particles below 30 µm as per Figure 4B, the ffc follows a 
single gradient when plotted against the amount of fines, independent of the type of fines 
added. This suggests that the size distribution of the particles <30 µm is less important than 
their overall proportion in determining flow properties. These findings are in agreement with 
a study by Guenette et al., where it was shown that the fines below 10 µm had the largest 
negative effect on the flow properties of lactose carriers for inhalation, but that also the fines 
fraction between 10 and 40 µm decreased the powder flowability (25). In their study, it was 
shown that particles larger than 40 µm had no impact on the powder flow properties.  
A plot of the normalized fluidization energy (FENorm) of the lactose pre-blends as a function of 
the percentage of particles <4.5 µm is shown in Figure 5A. These data suggest that the 
presence of micronized (LH300) fines had a different impact on the fluidization properties of 
the pre-blends than the milled fines (LH230 and LH210). For example, the addition of 10 wt-
% LH300 resulted in a FENorm of approximately 1.2 mJ/g, whereas a similar proportion of 
milled fines (LH230 and LH210) produced a FENorm of approximately 1.6 mJ/g. The 
relationship between FENorm and the proportion of fines below 30 µm present in the carriers 
is illustrated in Figure 5B. These data are scattered to a greater extent than those shown in 
Figure 4B. This indicates that flow and fluidization characteristics of the lactose pre-blends 
may be governed by different mechanisms. Therefore, measuring the fluidization properties 
of the pre-blends in addition to the flow properties may add value to the characterization of 
lactose carriers for DPI formulations. 
The flow and fluidization properties of the carriers indicate that addition of lactose fines to the 
carrier pre-blends increases the cohesion of the powder bulk both in terms of flow and 
fluidization properties. The data suggest that the increase in the cohesive strength is 
governed by the presence of lactose fines below approximately 30 µm, in agreement with 
the Geldart powder classification system (4).   
In vitro performance of DPI formulations prepared with the lactose pre-blends as 
carriers 
The in vitro aerosolization performance of budesonide formulations prepared using the 
lactose blends (Dose variation < 6% for all the blends) were tested with the Rotahaler and 
the Handihaler DPI devices, and are summarized in Table IV in terms of their fine particle 
fraction of emitted dose (FPFED) and mean mass aerodynamic diameter (MMAD) values. 
Rotahaler and Handihaler were chosen as the devices to represent opposite ends of the 
spectrum of capsule based devices such that a possible link between the powder properties 
and the aerosolization performance in different types of capsule based devices could be 
assessed.  
Table IV highlights that only low concentrations of micronized fines are required to 
significantly improve DPI performance; in terms of fine particle fraction of emitted dose 
(FPFED), an addition of 5 wt-% or more of LH300 significantly (p<0.01) increased DPI 
formulation performance compared to the formulation prepared with LH100 alone on both 
the devices. These data suggest that the addition of micronized fines significantly affected 
the fine particle delivery performance of micronized budesonide in capsule based DPI 
devices. In the case of LH230, a 20 wt-% addition of the material was required to 
significantly improve aerosolization performance compared to LH100 on both the devices. 
Across the range of concentrations investigated, the addition of LH210 did not significantly 
increase performance compared to LH100 (p>0.05). These data show that the addition of 
milled lactose fines to a carrier-based lactose formulation that is aerosolized from a capsule-
based device does not necessarily improve DPI formulation performance. These findings are 
in agreement with previous studies by Zeng et al. and Adi et al. (11,24) that reported that 
micronized lactose fines were more efficient in improving DPI performance than coarser 
sized lactose fines. 
To evaluate the extent of drug deagglomeration from the two different devices upon 
aerosolization, the mean mass aerodynamic diameters (MMAD) of budesonide aerosolized 
from the different formulations were inspected (Table IV). The MMAD of formulations 
containing LH300 remained unchanged over the range of fines concentrations for both the 
devices, suggesting that the extent of deagglomeration had not significantly changed for the 
formulations containing micronized fines despite the increasing fines content (Table IV). On 
the contrary, for the formulations prepared with the milled fines, LH230 and LH210, an 
increasing trend in the MMAD was measured as the fines content of the formulations was 
increased. For the Rotahaler, the MMAD was significantly higher for 5 and 10 wt-% LH230 
formulations and the 10 and 20 wt-% LH210 formulations than for the LH100 formulation. 
For the Handihaler, formulations containing LH230 or LH210 had larger MMAD in 
comparison to the formulation prepared with LH100 only.  
Due to the similar trends apparent in the results, the FPFED and MMAD data suggest that the 
drug deagglomeration from the two very different devices investigated here is governed by 
the powder properties rather than the device properties. Based on the data, it appears that 
micronized fines lead to a more complete and consistent deagglomeration behaviour over a 
range of fines concentrations, whereas with the milled fines less pronounced impact on drug 
delivery, but a more pronounced effect on MMAD of the drug is observed.  These findings 
are in an agreement with a previous study, where changes in the values of MMAD were 
reported as lactose fines were added to DPI formulations. These changes were attributed 
the formation of drug-fines agglomerates that were distributed within the impactor (31).  
However, although at first sight it appears that the device properties do not significantly alter 
the trends in DPI formulation performance at least in terms of FPFED and MMAD, on closer 
inspection differences between the two devices are observed in the proportion of emitted 
drug. This is illustrated in Figure 6, where the proportions of budesonide recovered from the 
device and capsule (Retained dose), and from the mouthpiece, throat, pre-separator and the 
impactor stages (Emitted dose) on the two different devices from the different formulations 
are shown. The addition of micronized fines (LH300) increases the retained dose of 
budesonide for Rotahaler from approximately 30 to 45% over the range of the fines 
concentrations investigated (Figure 6A), whereas does not have an impact on the proportion 
of drug recovered from Handihaler, with the retained dose remaining constant at 
approximately 20% (Figure 6D). With finer of the milled fines, LH230, the retained dose of 
budesonide remains constant at ~30% until a fines concentration of 20 wt-%, when an 
increase to ~40% is observed (Figure 6B). With Handihaler, the retained dose remains 
constant at approximately 20% over the range of LH230 concentrations (Figure 6E). With the 
larger of the milled fines, LH210, the retained dose slightly increases from ~30 to 35% for 
Rotahaler over the range of concentrations (Figure 6C). With Handihaler, once again, no 
clear increasing trends are observed in the retention pattern over the range of fines 
concentrations (Figure 6F). These data suggest that Handihaler is capable of emptying the 
device and capsule in a consistent manner independent of the powder properties, whereas 
the device emptying efficiency of the Rotahaler may be dependent on the powder properties.  
Therefore, in vitro performance data suggest that the powder properties govern the drug 
deagglomeration performance regardless of the device, whereas the device properties 
influence the efficiency of drug emission from the device and capsule during the 
aerosolization process. Therefore, to optimize drug delivery from a DPI product, it is 
recommended the powder properties are considered carefully when a low resistance device 
without a significant mechanism to aid capsule and device emptying is paired with a DPI 
formulation. 
Relationship between powder flow and fluidization of the carrier-based lactose 
formulation and in vitro aerosolization performance 
Fluidisation of the powder formulation is a key step in the aerosolisation process of APIs 
from DPI drug products. Furthermore, as the largest constituent of DPI formulations is the 
carrier lactose, then the fluidisation properties of the carrier lactose pre-blends may provide 
information regarding the aerosolization efficiency of DPI formulations. Indeed, recent 
studies have reported a correlation between carrier lactose fluidisation energy and in vitro 
performance of DPI model formulations (12,20), although opposing findings have also been 
reported especially in the case of ternary DPI formulations, where it was concluded that the 
measurements under aeration did not provide predictive capabilities for understanding DPI 
formulation performance (32). However, to further understand the possible mechanistic 
relationship between the fluidization properties of the carriers and the respective formulation 
performance, the in vitro aerosolisation performance of the formulations was compared to 
the fluidization behaviour of the carriers.   
The FPFED of the formulations used in the current study are plotted against the normalized 
fluidization energy (FENorm) of the carrier blend for each of the formulations and shown in Fig 
7. In the case of the addition of micronized fines (LH300), there was a linear relationship 
between the energy required to fluidize the formulation and the fine particle fraction delivered 
up to 10 wt-% fines concentration with both the Rotahaler and the Handihaler (Figure 7A and 
7C). However, at 20 wt-% concentration, despite the increase in the fluidization energy, the 
fine particle fraction decreased. Similarly, there was a linear relationship between fluidisation 
energy and FPFED for both the Rotahaler and Handihaler upon the addition of milled fines 
LH230 and LH210 (Figure 7B and 7D). However, as shown in Fig. 7, an increase in 
fluidization energy upon addition of milled fines only corresponded to a very slight 
improvement in the performance.  
The current study has shown that on comparing the fluidization energy of a range of different 
lactose systems containing milled or micronized lactose fines, a universal correlation 
between the fluidisation energy and DPI performance is not strong. However, when 
comparing the fluidization energy and in vitro performance within a given lactose system, the 
relationship between fluidization energy and in vitro performance was established. These 
data therefore, suggest the fluidization energy measurement is more suitable for 
discriminating flow and fluidization properties between lactose systems that contain lactose 
fines of similar particle size. Therefore we suggest that powder flow and fluidisation 
measurements could potentially be used in routine manufacturing as an additional quality-
by-design (QbD) tool for ensuring that the flow and fluidization characteristics of the raw 
material do not differ from what is normally used for a formulation. The findings of the current 
study also indicate that the increased cohesion theory (12) does not provide a universal 
explanation for improved DPI performance in the presence of lactose fines.  
Conclusions 
 
The current study showed that the addition of lactose fines increased the cohesion of the 
bulk powder and increased the fluidization energy of the lactose system. The increased 
cohesion of lactose pre-blends could be determined using both static and dynamic powder 
rheology measurements such as ffc and BFENorm, respectively. It was shown that for 
characterising general powder flow properties, similar results are obtained with both the 
static and dynamic testing methods. Therefore, both these approaches can be 
recommended for characterising general powder flow properties of lactose carriers used in 
DPI formulations. It was shown that amount of fines below 30 µm governed the powder flow 
and fluidisation properties of the lactose carriers and that the powder properties govern the 
deagglomeration properties of a formulation, whereas the device properties play a role in 
determining the extent of emitted dose. Increase in formulation performance was observed 
with micronized fines over the range of concentrations studied, whereas the addition of 
milled fines did not necessarily result in an improved formulation performance. There was no 
universal correlation observed between the fluidization properties and DPI performance, with 
milled and micronized fines producing different responses. The results therefore suggest that 
increased cohesion theory (12) does not universally explain the improved DPI performance 
in the presence of lactose fines. However, flow and fluidisation properties may be suited for 
predicting performance of formulations prepared with carriers of similar particle size 
characteristics and their use as an additional QbD tool in formulation manufacture can be 
recommended. 
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Tables 
 
Table I Particle size distributions of the coarse lactose (LH100) and the lactose fines (LH300, 
LH230 and LH210) used in the study in terms of d10, d50 and d90 of density distributions. 
The data represents mean ± standard deviation (S.D.), n=5. 
 d10 ± S.D. (µm) d50 ± S.D. (µm) d90 ± S.D. (µm) 
LH100 42.21 ± 0.46 101.59 ± 0.40 157.80 ± 0.51 
LH300 0.84 ± 0.01 2.41 ± 0.07 7.76 ± 0.27 
LH230 1.31 ± 0.01 8.05 ± 0.06 21.97 ± 0.09 
LH210 1.64 ± 0.01 14.3 ± 0.22 39.45 ± 0.54 
 
Table II Particle size distributions of the lactose carriers used in the study in terms of d10, 
d50 and d90. The data represents mean ± standard deviation (S.D.), n=5. In addition, the 
mean values (n=5) of proportion of particles finer than 4.5 and 30 µm present in the carriers 
are tabulated.  
 
d10 ±  S.D. 
(µm) 
d50 ± S.D. 
(µm) 
d90 ±  S.D. 
(µm) 
<4.5 µm 
(%) 
<30 µm 
(%) 
LH100 44.30 ± 1.58 103.37 ± 1.01 159.62 ± 0.56 1.29 6.24 
+2.5% LH300 23.44 ± 1.01 99.66 ± 0.35 161.02 ± 2.15 4.88 11.48 
+5% LH300 5.22 ± 0.32 95.19 ± 0.79 157.27 ± 3.31 9.34 17.03 
+10% LH300 2.08 ± 0.02 87.30 ± 0.85 154.55 ± 3.77 17.43 26.97 
+20% LH300 1.73 ± 0.06 60.76 ± 2.11 139.93 ± 3.40 23.04 42.75 
+2.5% LH230 26.41 ± 0.84 99.78 ± 0.37 160.88 ± 0.31 2.76 10.95 
+5% LH230 14.70 ± 0.29 96.58 ± 0.64 159.82 ± 3.02 4.32 15.13 
+10% LH230 7.33 ± 0.14 89.55 ± 0.38 156.65 ± 1.02 7.23 23.23 
+20% LH230 3.26 ± 0.21 67.18 ± 1.55 134.32 ± 2.77 12.47 38.15 
+2.5% LH210 31.53 ± 1.05 100.23 ± 0.64 158.57 ± 2.12 1.98 9.56 
+5% LH210 23.63 ± 0.61 97.72 ± 0.62 159.85 ± 1.74 2.62 12.27 
+10% LH210 14.25 ± 0.27 91.51 ± 0.70 156.18 ± 3.04 4.08 17.89 
+20% LH210 8.72 ± 0.12 79.30 ± 1.53 151.45 ± 6.27 6.02 26.79 
 
 
 
 
 
 
 
 
 
Table III Summary of the powder flow and fluidization properties of the carriers as 
characterized by flowability number (ffc), normalized basic flow energy (BFENorm), flow rate 
index (FRI), Normalized fluidization energy (FENorm), dynamic flow index (DFI), Carr’s index 
and Hausner ratio. The data represents mean ± Standard deviation (S.D.), n=3. 
 
ffc 
 ± 
 S.D. 
BFENorm  
± S.D.  
(mJg
-1
) 
FRI  
± 
 S.D. 
FENorm          
± S.D.  
(mJg
-1
) 
LH100 5.55±0.23 25.12±0.40 1.02±0.01 0.70±0.08 
+2.5% LH300 4.35±0.25 22.06±0.31 1.10±0.01 0.84±0.09 
+5% LH300 3.43±0.10 20.34±0.49 1.19±0.02 1.23±0.07 
+10% LH300 2.25±0.06 15.68±0.54 1.52±0.02 1.44±0.07 
+20% LH300 1.63±0.02 9.93±0.14 2.41±0.15 1.75±0.01 
+2.5% LH230 4.28±0.26 21.65±0.11 1.06±0.00 0.95±0.10 
+5% LH230 3.45±0.37 19.37±0.17 1.09±0.00 1.12±0.13 
+10% LH230 2.59±0.04 16.07±0.15 1.29±0.01 1.54±0.10 
+20% LH230 1.74±0.03 10.52±0.33 1.81±0.06 1.93±0.17 
+2.5% LH210 4.97±0.13 23.48±0.42 1.03±0.01 0.78±0.02 
+5% LH210 4.14±0.19 21.11±0.59 1.06±0.05 1.00±0.14 
+10% LH210 3.51±0.14 19.54±0.31 1.14±0.01 1.04±0.09 
+20% LH210 2.28±0.02 13.24±0.10 1.41±0.02 1.60±0.03 
 
 
Table IV In vitro performance of the formulations prepared with the lactose pre-blends as the 
carriers in terms of fine particle fraction of emitted dose (FPFED) and mean mass 
aerodynamic diameter (MMAD). The data for FPFED represents mean ± standard deviation, 
n=3. The data for MMAD represents mean ± geometric standard deviation (GSD), n=3. 
 
Rotahaler Handihaler 
FPFED ± S.D. 
(%) 
MMAD ± 
GSD (µm) 
FPFED ± S.D. 
(%) 
MMAD ± 
GSD (µm) 
LH100 15.68 ± 0.42 3.28 ± 1.92 15.21 ± 1.55 3.00 ± 1.81 
 +2.5% LH300 20.18 ± 1.56 3.73 ± 1.79 22.72 ± 2.42 3.16 ± 1.74 
 +5% LH300 28.37 ± 2.26 3.71 ± 1.77 33.94 ± 1.78 3.01 ± 1.73 
 +10% LH300 40.02 ± 4.03 3.41 ± 1.82 43.07 ± 0.62 2.95 ± 1.77 
 +20% LH300 37.80 ± 3.43 3.48 ± 1.96 37.00 ± 4.39 3.22 ± 1.87 
 +2.5% LH230 17.31 ± 3.02 3.50 ± 2.02 17.63 ± 1.11 3.26 ± 1.90 
 +5% LH230 16.13 ± 1.95 4.31 ± 1.86 20.84 ± 3.39 3.31 ± 1.97 
 +10% LH230 20.92 ± 2.55 4.40 ± 1.87 22.50 ± 2.10 3.62 ± 1.98 
 +20% LH230 32.07 ± 2.85 3.74 ± 2.12 31.51 ± 0.31 3.45 ± 2.08 
 +2.5% LH210 14.52 ± 1.34 3.60 ± 1.88 16.18 ± 0.70 3.26 ± 1.80 
 +5% LH210 15.39 ± 2.57 3.66 ± 1.89 18.27 ± 0.21 3.34 ± 1.87 
 +10% LH210 18.11 ± 3.33 4.13 ± 1.83 19.36 ± 3.67 3.41 ± 1.85 
 +20% LH210 17.95 ± 0.94 4.04 ± 2.05 18.82 ± 1.08 3.56 ± 2.04 
 
 
 
 
 
Legend to Figures 
Figure 1 900x magnification scanning electron micrographs of A) LH100 B) LH300 C) LH230 
and D) LH210 
 
Figure 2 The relationship between the ffc number measured on the Schulze RST-XS ring 
shear tester and the normalized basic flow energy (BFENorm) measured on the FT4 powder 
rheometer for the individual lactose pre-blends investigated in the study. The data 
represents mean ± standard deviation, n=3.  
 
Figure 3 The relationship between flow rate index (FRI) and flowability number ffc for the 
lactose carriers investigated in the study. The data represents mean ± standard deviation, 
n=3. 
 
Figure 4 The relationship between ffc and the proportion of fines A) <4.5µm and B) <30µm in 
the different lactose pre-blends. The data for ffc represents mean ± standard deviation, n=3. 
The data for proportion of particles finer than 4.5 µm and 30 µm represents mean of 5 
determinations. 
 
Figure 5 The relationship between the proportion of fines below A) 4.5 µm and B) 30 µm 
present in the carrier and the normalized fluidization energy (FENorm) of the lactose pre-
blends. The data for FENorm represents mean ± standard deviation, n=3. The data for 
proportion of particles finer than 4.5 µm and 30 µm represents mean of 5 determinations. 
 
Figure 6 The proportion of budesonide recovered the device and capsule (Retained dose, 
black bars) and from mouthpiece, throat, pre-separator and impactor stages (Emitted dose, 
grey bars) for the series of formulations prepared with A) LH300, B) LH230 and C) LH210 
aerosolized on a Rotahaler and D) LH300, E) LH230 and F) LH210 aerosolized on a 
Handihaler.  The data represents the mean of three repeated determinations. 
 
Figure 7 The relationship between the normalized fluidization energy (FENorm) of the carrier 
pre-blends and the DPI performance in terms of fine particle fraction of emitted dose (FPFED) 
for formulations prepared with A) micronized (LH300) and B) milled fines (LH230 and 
LH210) aerosolized on a Rotahaler and C) micronized (LH300) and D) milled fines (LH230 
and LH210) aerosolized on a Handihaler. The data represents mean ± standard deviation, 
n=3. 
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